Royal Bank of Canada’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $111K | Sell |
4,126
-606
| -13% | -$20.4K | ﹤0.01% | 5065 |
|
|
2025
Q4 | $202K | Sell |
4,732
-1,475
| -24% | -$55.6K | ﹤0.01% | 4756 |
|
|
2025
Q3 | $176K | Sell |
6,207
-4,108
| -40% | -$123K | ﹤0.01% | 5164 |
|
|
2025
Q2 | $193K | Sell |
10,315
-3,507
| -25% | -$66.5K | ﹤0.01% | 5189 |
|
|
2025
Q1 | $248K | Sell |
13,822
-4,087
| -23% | -$82.9K | ﹤0.01% | 4550 |
|
|
2024
Q4 | $302K | Buy |
17,909
+16,184
| +938% | +$310K | ﹤0.01% | 4471 |
|
|
2024
Q3 | $28K | Sell |
1,725
-4,013
| -70% | -$47.2K | ﹤0.01% | 5981 |
|
|
2024
Q2 | $46K | Buy |
5,738
+5,330
| +1,306% | +$55.8K | ﹤0.01% | 5697 |
|
|
2024
Q1 | $6K | Sell |
408
-5,085
| -93% | -$68.5K | ﹤0.01% | 6400 |
|
|
2023
Q4 | $79K | Buy |
5,493
+2,793
| +103% | +$28.6K | ﹤0.01% | 5755 |
|
|
2023
Q3 | $30K | Buy |
2,700
+1,082
| +67% | +$13K | ﹤0.01% | 6029 |
|
|
2023
Q2 | $20K | Sell |
1,618
-6,299
| -80% | -$85.2K | ﹤0.01% | 6219 |
|
|
2023
Q1 | $105K | Sell |
7,917
-16,487
| -68% | -$262K | ﹤0.01% | 5144 |
|
|
2022
Q4 | $367K | Buy |
24,404
+15,037
| +161% | +$138K | ﹤0.01% | 4383 |
|
|
2022
Q3 | $111K | Buy |
9,367
+8,864
| +1,762% | +$120K | ﹤0.01% | 5234 |
|
|
2022
Q2 | $6K | Sell |
503
-1,047
| -68% | -$21K | ﹤0.01% | 6592 |
|
|
2022
Q1 | $46K | Sell |
1,550
-2,692
| -63% | -$72.9K | ﹤0.01% | 6157 |
|
|
2021
Q4 | $113K | Buy |
4,242
+1,989
| +88% | +$60K | ﹤0.01% | 5846 |
|
|
2021
Q3 | $82K | Buy |
2,253
+633
| +39% | +$24.9K | ﹤0.01% | 5844 |
|
|
2021
Q2 | $71K | Sell |
1,620
-156
| -9% | -$5.89K | ﹤0.01% | 5804 |
|
|
2021
Q1 | $60K | Buy |
+1,776
| New | +$70.3K | ﹤0.01% | 5781 |
|
|
2020
Q4 | – | Sell |
-93
| Closed | -$2K | – | 7252 |
|
|
2020
Q3 | $2K | Sell |
93
-1,200
| -93% | -$29.5K | ﹤0.01% | 6334 |
|
|
2020
Q2 | $24K | Sell |
1,293
-1,642
| -56% | -$29.5K | ﹤0.01% | 5519 |
|
|
2020
Q1 | $45K | Buy |
2,935
+2,784
| +1,844% | +$59.3K | ﹤0.01% | 5206 |
|
|
2019
Q4 | $3K | Buy |
151
+1
| +0.7% | +$21 | ﹤0.01% | 6498 |
|
|
2019
Q3 | $3K | Sell |
150
-2
| -1% | -$41 | ﹤0.01% | 6216 |
|
|
2019
Q2 | $4K | Hold |
152
| – | – | ﹤0.01% | 6398 |
|
|
2019
Q1 | $4K | Sell |
152
-98
| -39% | -$2.24K | ﹤0.01% | 6354 |
|
|
2018
Q4 | $5K | Sell |
250
-221
| -47% | -$6.24K | ﹤0.01% | 6171 |
|
|
2018
Q3 | $15K | Buy |
471
+221
| +88% | +$6.63K | ﹤0.01% | 5823 |
|
|
2018
Q2 | $7K | Hold |
250
| – | – | ﹤0.01% | 5939 |
|
|
2018
Q1 | $9K | Sell |
250
-8
| -3% | -$320 | ﹤0.01% | 5756 |
|
|
2017
Q4 | $10K | Sell |
258
-824
| -76% | -$31.4K | ﹤0.01% | 5865 |
|
|
2017
Q3 | $27K | Buy |
1,082
+1,048
| +3,082% | +$25.5K | ﹤0.01% | 5797 |
|
|
2017
Q2 | $1K | Sell |
34
-451
| -93% | -$12.3K | ﹤0.01% | 6427 |
|
|
2017
Q1 | $16K | Sell |
485
-11
| -2% | -$280 | ﹤0.01% | 5743 |
|
|
2016
Q4 | $12K | Buy |
496
+446
| +892% | +$12.8K | ﹤0.01% | 6013 |
|
|
2016
Q3 | $2K | Sell |
50
-22
| -31% | -$631 | ﹤0.01% | 6189 |
|
|
2016
Q2 | $2K | Sell |
72
-10
| -12% | -$249 | ﹤0.01% | 6152 |
|
|
2016
Q1 | $2K | Sell |
82
-13
| -14% | -$321 | ﹤0.01% | 6137 |
|
|
2015
Q4 | $3K | Sell |
95
-395
| -81% | -$12K | ﹤0.01% | 6292 |
|
|
2015
Q3 | $12K | Sell |
490
-91
| -16% | -$2.72K | ﹤0.01% | 5810 |
|
|
2015
Q2 | $19K | Buy |
581
+552
| +1,903% | +$21.1K | ﹤0.01% | 5730 |
|
|
2015
Q1 | $1K | Buy |
29
+7
| +32% | +$192 | ﹤0.01% | 5991 |
|
|
2014
Q4 | $1K | Hold |
22
| – | – | ﹤0.01% | 6051 |
|
|
2014
Q3 | $0 | Hold |
22
| – | – | ﹤0.01% | 6099 |
|
|
2014
Q2 | $1K | Hold |
22
| – | – | ﹤0.01% | 5826 |
|
|
2014
Q1 | $1K | Hold |
22
| – | – | ﹤0.01% | 5811 |
|
|
2013
Q4 | $1K | Sell |
22
-780
| -97% | -$22.9K | ﹤0.01% | 5837 |
|
|
2013
Q3 | $29K | Sell |
802
-606
| -43% | -$22.1K | ﹤0.01% | 5039 |
|
|
2013
Q2 | $47K | Buy |
+1,408
| New | +$63.8K | ﹤0.01% | 4691 |
|
Other funds holding RIGL
AC
VCM
Royal Bank of Canada's RIGL Position: Q1 2026 in Review
Royal Bank of Canada reduced its Rigel Pharmaceuticals (RIGL) stake by 13% in Q1 2026, selling an estimated $20.4K and leaving 4,126 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #5065.
Royal Bank of Canada first reported a position in RIGL in Q2 2013 and has held it in 51 quarters since. The position peaked at $367K in Q4 2022. 159 funds tracked by Wall St. Rank hold RIGL as of Q1 2026.
- Royal Bank of Canada held 4,126 shares of Rigel Pharmaceuticals worth $111K as of Q1 2026.
- Royal Bank of Canada sold 606 Rigel Pharmaceuticals shares in Q1 2026, an estimated $20.4K.
- Rigel Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5065 holding.
- Royal Bank of Canada first reported a position in Rigel Pharmaceuticals in Q2 2013 and has held it in 51 quarters since.
- Royal Bank of Canada's Rigel Pharmaceuticals position peaked at $367K in Q4 2022.
- 159 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.